GEHC Stock Forecast & Price Target

GE HealthCare Techs is well positioned for mid-single-digit organic revenue growth and high-single-digit or better EPS growth, supported by a balanced mix of capital, service, and recurring revenue streams that make up about half of sales. Its capital book-to-bill strength, $23.9 billion backlog as of 2Q26, and a 2026 organic revenue guide of 3-4% suggest demand resilience, while margin expansion is aided by disciplined cost control and a targeted 17-20%+ long-term operating margin profile. The $945 million Sofie Biosciences acquisition, expected to close in 1H27, should further support growth by vertically integrating radiopharmaceuticals, adding a phase 3 asset, and being accretive to revenue growth, operating margin, and EPS in the first full year.

GE HealthCare Techs is facing a bearish setup because its core growth drivers are constrained by macro and competitive pressures: management expects China to decline year over year in 2026, hospital capital budgets are under pressure, and softer imaging and capital equipment demand could spill over into services. The company’s bear case already assumes only low-single-digit revenue growth, and even though its recurring base is meaningful, pricing and volume risk remain in products like Omnipaque, where a generic launch could trim PDx growth by about 150 bps. Added uncertainty from tariff and inflation impacts, supply-chain risk, and execution on acquisitions or pipeline initiatives reinforces limited upside and slower earnings growth.